Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1624
This examiner grants 45% of resolved cases
Andre Mach is an examiner in Tech Center 1600 and Art Unit 1615. The data includes 78 resolved cases for this examiner. Within these 78 resolved cases, the allowance rate is 44.9 percent. This 44.9 percent rate suggests a moderate probability of securing a patent grant. The median days to allowance for this examiner is 1244, which represents the typical time to reach a successful conclusion in Art Unit 1615.
The interview lift is 51.7 percent. This 51.7 percent lift indicates that cases with an interview are significantly more likely to be allowed. For practitioners, this positive lift suggests that an interview is an exceptionally effective tool for advancing prosecution in Tech Center 1600. The 1244 median days to allowance provides a clear timeline for applicants to follow when planning their strategy.
With 78 resolved cases, the examiner's performance is well-defined. The 44.9 percent allowance rate and the 51.7 percent interview lift are critical metrics for developing a prosecution plan. Practitioners can use the 1244-day median to inform their clients about the expected duration of the process. These figures from Art Unit 1615 offer a data-grounded understanding of the examiner's tendencies.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17376138 | SYNTHETIC HEPARIN MIMETICS AND USES THEREOF | Non-Final OA | Trustees of Boston University |
| 18911383 | ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID | Non-Final OA | The Procter & Gamble Company |
| 18029028 | STROKE TREATMENT | Non-Final OA | President and Fellows of Harvard College |
| 18499534 | PROCESS AND COMPOSITION MATTER OF NANOPARTICLE FORMULATION FOR SYSTEMIC TREATMENT OF SEPSIS | Final Rejection | Purdue Research Foundation |
| 17252450 | COMPOSITION COMPRISING AT LEAST TWO DIFFERENT ANIONIC SURFACTANTS, NON-IONIC AND AMPHOTERIC SURFACTANTS, AND CATIONIC OR AMPHOTERIC POLYMERS | Non-Final OA | L'OREAL |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | Non-Final OA | Quicksilver Scientific, Inc. |
| 18477748 | TRANSLUCENT COSMETIC COMPOSITION | Non-Final OA | Amorepacific Corporation |
| 18542454 | DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME | Non-Final OA | Axogen Corporation |
| 17416680 | Pest Repellent Composition | Non-Final OA | Kao Corporation |
| 18695605 | BONE REPAIR DEVICE AND SURGICAL KIT | Non-Final OA | FUJITA ACADEMY |
| 17275266 | NANOPARTICLE FORMULATIONS AND METHODS OF THEIR USE | Non-Final OA | Children's Medical Center Corporation |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | Non-Final OA | THE UNIVERSITY OF TOLEDO |
| 18254912 | METHOD FOR FABRICATING MICROROBOT FOR DELIVERY OF CELL THERAPY PRODUCT AND MICROROBOT ACCORDING THERETO | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18696137 | DRY CREAMS AND TOPICAL DELIVERY SYSTEMS | Non-Final OA | UEA Enterprises Limited |
| 18690241 | METHODS AND COMPOSITIONS TO REDUCE CELLULAR DEPOSITION, AND HYDROCEPHALUS SHUNT FAILURE | Non-Final OA | Wayne State University |
| 18245565 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | Final Rejection | AUSPEX PHARMACEUTICALS, INC. |
| 18812747 | DIHYDROMYRICETIN SPRAY-DRIED DISPERSION FORMULATIONS AND METHODS FOR FORMING THEM | Non-Final OA | Cheers Health, Inc. |
| 18837388 | COLESTYRAMINE FOR TREATING WOUNDS, BACTERIAL INFECTIONS OF THE SKIN, AND INFLAMMATORY SKIN LESIONS | Non-Final OA | Dietrich SEIDEL |
| 18756663 | BOWEL CLEANSING COMPOSITION WITH REDUCED DOSAGE ON THE DAY OF EXAMINATION | Non-Final OA | Hyan Yee Kang |
| 17414842 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | Non-Final OA | LUNELLA BIOTECH, INC. |
| 17918012 | COMPOSITIONS AND METHODS FOR EMERGENCY RESCUE | Final Rejection | Purdue Pharma L.P. |
| 18037211 | DEVICES, COMPOUNDS AND METHODS FOR INSECT CONTROL | Non-Final OA | Agriculture Victoria Services Pty Ltd |
| 18405569 | Method for Manufacturing a Calcified Tissue Substitute | Final Rejection | Marine Biomedical Pty Ltd |
| 18554118 | ROPIVACAINE SUSPENSION INJECTION, AND PREPARATION METHOD THEREFOR | Non-Final OA | ZHEJIANG CUIZE PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 18453355 | TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR | Final Rejection | Sol-Gel Technologies Ltd. |
| 18278017 | Compositions for ophthalmic care | Final Rejection | ReBio Technologies Oy |
| 17757455 | SYNOVIAL FLUID SUBSTITUTES | Final Rejection | Altergon S.A. |
| 18252432 | NON-AQUEOUS GEL COMPOSITION | Non-Final OA | Acousia Therapeutics GmbH |
| 18035923 | Small Molecule Formulation | Non-Final OA | Dialectic Therapeutics, Inc. |
| 18022353 | ETOPOSIDE TONIRIBATE FORMULATION | Non-Final OA | CELLACT PHARMA GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy